A trial of brolitene in the treatment of spasticity.
Perkin G D, Aminoff M J·British journal of clinical pharmacology
A new anti-spasticity agent, brolitene, has been assessed in patients with spasticity of spinal or cerebral origin. Twenty-seven patients were entered in a double-blind cross-over trial lasting 6 weeks, using a fixed dose of six tablets (1200 mg brolitene) per day. Clinical assessment failed to show any therapeutic eff…